EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Parkinson's disease under dopamine replacement therapy as a human framework for studying addiction‐relevant mechanisms

Vanessa Fleury iD, Elvira Pirondini, Damien Benis, Tiffany Corbet, Gabriel Thorens, Christian Lüscher, Paul Krack

Psychiatry and Clinical Neurosciences · 2026-11 · 80 (11) · 877-888

DOI: 10.1111/pcn.70118 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Psychiatry and Clinical Neurosciences, online erschienen am 11.08.2026. Verfasst von Vanessa Fleury und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Geneva University Hospital, Geneva, Switzerland. Hauptthemen laut MEDLINE: Parkinson Disease, Disruptive, Impulse Control, and Conduct Disorders, Behavior, Addictive, Dopamine. Die Arbeit nennt 157 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swiss National Science Foundation, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Addiction is a chronic relapsing condition characterized by compulsive reward seeking and impaired behavioral control, associated with major individual and societal burden. Mechanistic investigation in humans remains constrained by ethical limitations, uncontrolled exposure histories, and ecological confounds. Parkinson's disease treated with dopamine replacement therapy provides a human framework for investigating addiction‐relevant mechanisms under controlled dopaminergic modulation. We performed a narrative synthesis of clinical, neuropsychological, pharmacological, neuroimaging, and electrophysiological evidence linking impulse control disorders and dopamine dysregulation syndrome in Parkinson's disease to dimensional and circuit‐based models of addiction. We examined phenotypic and neurobiological convergences, experimental opportunities, and translational relevance while outlining its boundary conditions. A subset of Parkinson's disease patients exposed to dopamine replacement treatment develops impulse control disorders and dopamine dysregulation syndrome. Impulse control disorders comprise heterogeneous behavioral phenotypes that share selected dimensions with behavioral addictions, whereas dopamine dysregulation syndrome most closely approximates pharmacological substance use disorders. These phenotypes share selected addiction‐related dimensions, including craving, impaired control, compulsive reward‐seeking, and persistence despite harm, while showing partial clinical and neurobiological convergence with behavioral addictions and substance use disorders. Parkinson's disease patients with neuropsychiatric fluctuations may represent a sensitized vulnerability state in which dopaminergic modulation dynamically influences reward processing, motivation, and compulsive behaviors. Parkinson's disease under dopamine replacement therapy enables within‐subject dopaminergic manipulation, longitudinal observation, prospective assessment of vulnerability traits, multimodal neurobiological investigation, and reduced environmental confounding. It therefore provides a unique human window for investigating addiction‐relevant mechanisms under controlled dopaminergic modulation, complementing animal models while remaining constrained by disease‐specific boundary conditions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseDisruptive, Impulse Control, and Conduct DisordersBehavior, AddictiveDopamineDopamine AgentsHumans

Stichwörter der Autor:innen

Parkinson's diseasebehaviordopamineimpulse control disordersubstance‐related disorders

Substanzen

DopamineDopamine Agents

Autor:innen und Institutionen

  • Department of Neurology, Geneva University Hospital, Geneva, Switzerland.
  • Faculty of Medicine, University of Geneva, Rue Michel-Servet 1, Geneva, Switzerland.
  • Rehabilitation Neural Engineering Laboratories, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Physical Medicine and Rehabilitation, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Neuroscience of Emotion and Affective Lab, University of Geneva, Geneva, Switzerland.

ORCID-Profile: Vanessa Fleury

Förderung

  • Swiss National Science Foundation
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Zitieren

APA

Fleury, V., Pirondini, E., Benis, D., Corbet, T., Thorens, G., Lüscher, C., & Krack, P. (2026). Parkinson's disease under dopamine replacement therapy as a human framework for studying addiction‐relevant mechanisms. Psychiatry and Clinical Neurosciences, 80(11), 877-888. https://doi.org/10.1111/pcn.70118

Vancouver

Fleury V, Pirondini E, Benis D, Corbet T, Thorens G, Lüscher C, et al. Parkinson's disease under dopamine replacement therapy as a human framework for studying addiction‐relevant mechanisms. Psychiatry and Clinical Neurosciences. 2026;80(11):877-888. doi:10.1111/pcn.70118

BibTeX
@article{Fleury2026,
  author = {Fleury, Vanessa and Pirondini, Elvira and Benis, Damien and Corbet, Tiffany and Thorens, Gabriel and Lüscher, Christian and Krack, Paul},
  title = {Parkinson's disease under dopamine replacement therapy as a human framework for studying addiction‐relevant mechanisms},
  journal = {Psychiatry and Clinical Neurosciences},
  year = {2026},
  volume = {80},
  number = {11},
  pages = {877--888},
  doi = {10.1111/pcn.70118}
}
Kostenlos starten →